NeuRx Diaphragm Pacing System for treating ALS
Synapse Biomedical, Inc. announces in a News Release that the U.S. FDA has approved NeuRx Diaphragm Pacing System (DPS)® for treating amyotrophic lateral sclerosis (ALS) patients who have stimulatable diaphragms and are experiencing chronic hypoventilation.
The FDA Humanitarian Device Exemption (HDE) marketing approval is based on demonstration that NeuRx DPS® could help ALS patients live longer and sleep better than the current standard of care, alone. These findings are the result of a multicenter clinical trial.
Read more on Medgadget.
Set as favorite
Bookmark
Email This
Hits: 75
Comments (0)
Write comment
Show/Hide comment form
You must be logged in to post a comment. Please register if you do not have an account yet.
